

# Journal of Visualized Experiments

## Cell-free Protein Expression Using the Rapidly Growing Bacterium *Vibrio Natriegens*

--Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE59495R1
<b>Full Title:</b>	Cell-free Protein Expression Using the Rapidly Growing Bacterium <i>Vibrio Natriegens</i>
<b>Keywords:</b>	Vibrio natriegens; crude cell extract, cell-free system; TX-TL; in-vitro protein synthesis; high-throughput screen; rapid protein expression
<b>Corresponding Author:</b>	Daniel Wiegand UNITED STATES
<b>Corresponding Author's Institution:</b>	
<b>Corresponding Author E-Mail:</b>	Daniel.Wiegand@wyss.harvard.edu
<b>Order of Authors:</b>	Daniel Jordan Wiegand Henry H Lee Nili Ostrov George M Church
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Boston, MA, USA

**TITLE:**

**Cell-free Protein Expression Using the Rapidly Growing Bacterium *Vibrio Natriegens***

**AUTHORS AND AFFILIATIONS:**

Daniel J. Wiegand<sup>1,2</sup>, Henry H. Lee<sup>1</sup>, Nili Ostrov<sup>1</sup>, George M. Church<sup>1,2</sup>

<sup>1</sup>Department of Genetics, Harvard Medical School, Boston, MA 02115

<sup>2</sup>Wyss Institute for Biologically Inspired Engineering, Boston, MA 02115

Corresponding authors:

Nili Ostrov (nili\_ostrov@hms.harvard.edu)

George M. Church (gchurch@genetics.med.harvard.edu)

Email addresses of co-authors:

Daniel J. Wiegand (daniel.wiegand@wyss.harvard.edu)

Henry H. Lee (hhlee@genetics.med.harvard.edu)

**KEYWORDS:**

*Vibrio natriegens*, crude cell extract, cell-free system, TX-TL, in-vitro protein synthesis, high-throughput screen

**SUMMARY:**

Cell-free expression systems are powerful and cost-efficient tools for the high-throughput synthesis and screening of important proteins. Here, we describe the preparation of cell-free protein expression system using *Vibrio natriegens* for the rapid protein production using plasmid DNA, linear DNA, and mRNA template.

**ABSTRACT:**

The marine bacterium *Vibrio natriegens* has garnered considerable attention as an emerging microbial host for biotechnology due to its fast growth rate. A general protocol is described for the preparation of *V. natriegens* crude cell extracts using common laboratory equipment. This high yielding protocol has been specifically optimized for user accessibility and reduced cost. Cell-free protein synthesis (CFPS) can be carried out in small scale 10  $\mu$ L batch reactions in either a 96- or 384-well format and reproducibly yields concentrations of > 260  $\mu$ g/mL super folder GFP (sfGFP) within 3 hours. Overall, crude cell extract preparation and CFPS can be achieved in 1–2 full days by a single user. This protocol can be easily integrated into existing protein synthesis pipelines to facilitate advances in bio-production and synthetic biology applications.

**INTRODUCTION:**

Cell-free protein synthesis is a versatile and cost-effective method for the expression of valuable proteins or peptides<sup>1–4</sup>. Historically, cell-free protein synthesis has been performed using *Escherichia coli* expression systems; however, there has been a recent surge in using alternative, non-model organisms with novel properties as chassis for cell-free expression<sup>5–12</sup>. Organisms

with unique metabolic profiles are prime candidates as alternatives to *E. coli* cell-free systems. For example, the marine bacterium *Vibrio natriegens* is the fastest growing of all known organisms with an observed doubling time of less than 10 minutes<sup>13</sup>. This has garnered *V. natriegens* considerable attention as an emerging microbial host for research and biotechnology<sup>14–18</sup>. Given that the rapid growth rate of *V. natriegens* has been linked to high rates of protein synthesis and metabolic efficiency<sup>19–21</sup>, harnessing its cellular machinery for cell-free synthesis may significantly expand the toolkit for rapid protein production and high-throughput screening.

Recently, a cell-free *V. natriegens* expression system has been demonstrated which is capable of producing super folder GFP (sfGFP) at concentrations of > 260 µg/mL in 3 hours with a T7 promoter<sup>9</sup>. The overall aim of developing this method was to provide users with a highly accessible, cost-efficient, reproducible, and high-yielding cell-free protein expression system that can be prepared using common lab equipment in a short amount of time. This protocol utilizes 1 L cultures in shake flasks, cell lysis by pulse sonication, and small-scale batch reactions in a 96- or 384-well format to maximize parallelization and screening throughput. A long, sustained protein expression is made possible by supplementation of 3-phosphoglyceric acid (3-PGA) as an energy source<sup>8,22,23</sup>. Upon successfully completing this protocol, a user will have the capability to express a desired protein or set of proteins in a cell-free format using *V. natriegens* crude cell extract.

Starting from a glycerol stock, *V. natriegens* crude cell extracts are prepared from cells harvested at an optical density at 600 nm (OD<sub>600</sub>) of 1.0. A 1 L culture will yield approximately 2–3 mL of extract, which is sufficient for more than 800 cell-free reactions at 25% crude cell extract. Proteins can be expressed using plasmid DNA, linear DNA, or mRNA template; however, linear DNA template degradation by endogenous nucleases remains a major drawback when using wild type *V. natriegens* cell-free system<sup>9</sup>. Starting from *V. natriegens* cultures, protein useable for downstream applications can be achieved by a single user in 1–2 full days.

## PROTOCOL:

### 1. Preparation of *V. natriegens* crude cell extracts – bacterial culture

1.1. Prepare *V. natriegens* bacterial growth media LB-V2 as per **Table 1**. Sterilize the growth media by autoclaving. Allow media to reach to room temperature (RT). Store excess media at RT.

CAUTION: Wear proper personal protection equipment (PPE) and consult lab specific instructions when operating an autoclave.

1.2. Use a glycerol stock of wild type *V. natriegens* to inoculate 3 mL of LB-V2 media. Grow overnight at 30 °C while shaking at 225 rpm.

1.3. Wash 1 mL of the overnight culture by centrifugation at 10,600 x *g* on a benchtop centrifuge for 1 min. Aspirate the supernatant without disturbing the resulting pellet and resuspend in 1 mL of fresh LB-V2 media.

1.4. In an autoclaved 4 L baffled Erlenmeyer flask with sterile cover, add 1 L of fresh LB-V2 growth media. Inoculate using 1 mL of washed overnight culture (1:1000 dilution ratio). Grow culture at 30 °C while shaking at 225 rpm.

NOTE: *V. natriegens* cultures can be scaled up or down while maintaining the 1:1000 dilution ratio. For example, add 250 µL of washed overnight culture to 250 mL of fresh LB-V2 growth media in a 2 L baffled Erlenmeyer flask with sterile cover.

1.5. Monitor the culture's OD<sub>600</sub> using a spectrophotometer. When culture reaches OD<sub>600</sub> = 1.0 ± 0.2, harvest culture via centrifugation at 3500 x g for 20 min at 4 °C. Place pellet on ice.

NOTE: *V. natriegens* grows rapidly, so close monitoring of the culture is necessary. Growth to OD<sub>600</sub> = 1.0 should take approximately 1.5–2 h at the 1:1000 dilution ratio.

1.6. Aspirate the supernatant and immediately store the resultant bacterial pellet at -80 °C or directly proceed to cell lysis described in section 2.

NOTE: This step is a good stopping point; however, it is recommended that the pellet be processed immediately or within 1–2 days for best results.

## 2. Preparation of *V. natriegens* crude cell extracts – cell lysis

2.1. Prepare S30 lysis buffer as per Table 1 in sterile deionized (DI) water and adjust pH to 7.7 using glacial acetic acid.

CAUTION: Glacial acetic acid should be handled with proper PPE when adjusting the pH.

2.2. Cool S30 lysis buffer to approximately 4 °C in a refrigerator or on ice before beginning the cell lysis procedure.

NOTE: For a quick cool down, lysis buffer can be placed at -20 °C. Do not allow the buffer to freeze.

2.3. Place cell pellets on ice for 10–20 min or until completely thawed. Resuspend all pellets resulting from the same 1 L culture using 10 mL of cold S30 lysis buffer, then transfer suspension to a 50 mL tube. If pellets are not frozen in the refrigerator at -80 °C in step 1.6, proceed directly to resuspension.

NOTE: Increase the volume of S30 lysis buffer used to initially resuspend pellets as needed.

2.4. Centrifuge suspension at 3500 x g for 10 min at 4 °C. Aspirate the supernatant without disturbing the pellet. Wash the pellet a second time using 10 mL of cold S30 lysis buffer. Place pellet on ice.



2.5. In a cold room, add 500  $\mu$ L of cold S30 lysis buffer to the pellet in the 50 mL tube. Using a wide-bore pipette tip, resuspend the pellet and carefully transfer the entire pellet suspension to a 2 mL tube.

NOTE: If a wide bore pipette is not available, use a pair of scissors to cut the end of a 1 mL pipette tip to increase the bore for pellet transfer.

2.5.1. Transfer as much pellet as possible without significantly increasing the volume; however, the pellet should be resuspended in enough liquid to be sonicated, as indicated by a homogenous suspension in the 2 mL tube. Do not overfill the 2 mL tube. The suspension should not exceed 1.5 mL; split into multiple tubes if necessary.

2.6. Keep the cell pellet on ice and work in a cold room. Fill a 600 mL beaker with ice and place a 2 mL tube holder on top of the ice.

NOTE: It is helpful to place the tube holder near the side of the beaker, so the pellet suspension will be visible in the ice to monitor sonication progress (see **Figure 1**).

2.7. Vortex suspended pellet in 2 mL tube briefly to homogenize the cells, flick tubes to remove any cells on the bottom of the cap, and place into tube holder with cap open. Lower sonicator tip into the suspension so that it is just under the liquid surface.

2.8. Prepare the sonication set-up as depicted in **Figure 2** using a sonicator and probe with a  $\frac{1}{8}$ -inch tip diameter. Input the following settings into the sonicator control: 20 kHz frequency and 50% amplitude, pulse ON time: 10 s, pulse OFF time: 60 s.

2.9. Run the pulse sonication protocol for three cycles. If the total volume of the pellet suspension is > 500  $\mu$ L, run the pulse sonication protocol six times.

NOTE: Generally, 3–6 pulses are sufficient to lyse *V. natriegens* pellets; additional pulses may be required depending on sonicator. During sonication, use the adjustment knob platform to move the probe up and down to lyse any pellet that may have settled to the bottom of the tube. The tube can be removed from the holder and briefly vortexed to re-homogenize the suspension in between pulses. See discussion below for desired consistency of sonicated cells.

CAUTION: Wear appropriate hearing protection when sonicator is active.

2.10. Following sonication, centrifuge crude cell extract at 16,000  $\times g$  for 30–45 min at 4  $^{\circ}$ C or until lysate is free of any cellular debris as depicted in **Figure 3**.

2.11. In a cold room, aliquot 50  $\mu$ L of the resulting supernatants to new 2 mL tubes without disturbing the pellet.

NOTE: Any debris that is transferred accidentally into the new 2 mL tubes will drastically reduce extract's capacity for high yielding protein synthesis.

2.11.1. Optionally, set aside 10  $\mu$ L of cell extract for post-lysis protein quantification in a separate 2 mL tube (see step 2.13 below).

2.12. Flash freeze crude cell extracts by placing tubes into a tube holder with a dipping string attached as depicted in **Figure 4**. Submerge tubes into a Dewar containing liquid nitrogen and immediately place in a refrigerator at -80 °C until use.

CAUTION: Use appropriate PPE for handling liquid nitrogen including lab coat, safety glasses, face shield, cryogen apron, and gloves.

2.13. Optionally, quantify the total protein of the cell lysate using 10  $\mu$ L set aside from step 2.11.1 by diluting sample 1:100 in 1x phosphate-buffered saline (PBS) and using any standard total protein quantification assay such as Bradford assay, benzethonium chloride assay (BCA), etc.

### **3. Preparation of cell-free reaction components**

#### **3.1. General reaction components**

3.1.1. Prepare working stocks of Mg-glutamate and K-glutamate in 50 mL tubes with sterile DI water at concentrations of 100 mM and 2000 mM, respectively.

3.1.2. Prepare a working stock of 50% (w/v) polyethylene glycol (PEG)-8000 by adding 100 mL of sterile DI water to a 250 mL beaker. Place a small magnetic stirrer into the beaker. Weigh out 50 g of PEG-8000 and add to the 100 mL of water in the beaker.

3.1.3. Place the beaker on a heated stir plate set to 100 °C and stir at 250 rpm until PEG-8000 is in solution. Allow PEG-8000 liquid mixture to cool before transferring to 50 mL tubes.

#### **3.2. Energy solution master mix**

3.2.1. Prepare a 5 M solution of KOH by adding 140 g of KOH pellets to 500 mL of sterile DI water.

CAUTION: Prepare this solution in a chemical hood and wear PPE when handling strong bases. The solution will become hot so the bottle cap must be loose to prevent pressure build-up. Allow the KOH solution to reach RT before using.

3.2.2. Prepare a 1750 mM HEPES-KOH buffer by adding 20.85 g of HEPES to a 100 mL bottle. Slowly add sterile DI water until the volume reaches 40 mL. Vortex bottle to dissolve the HEPES. Use the 5 M KOH solution to adjust the pH to 8.0 and then bring the solution volume to 50 mL.

CAUTION: KOH should be handled with proper PPE when adjusting the pH.

3.2.3. Prepare the remaining 10x energy master mix stock components at the concentrations indicated in **Table 2** in sterile DI water and place each stock on ice. Thaw the 100 mM ATP, GTP, CTP, and UTP stocks at RT and place on ice.

NOTE: A thermomixer set to 37 °C and 350 rpm can be used to dissolve reagents into solution if necessary. Do not overheat or leave reagents on the thermomixer for an extended period of time.

3.2.4. In a 15 mL tube, add each energy solution master mix component in accordance to the order and volume specified in **Table 2**. Vortex the solution after each component is added. This will make 5 mL of 10x energy solution master mix.

3.2.5. Divide the 10x energy solution master mix into 200 µL aliquots in 2 mL tubes. Flash freeze each aliquot as performed in step 2.12. Immediately place them into the -80 °C refrigerator until use.

### **3.3. Amino acid master mix**

3.3.1. To prepare fresh 4x amino acid master mix, begin by thawing each amino acid stock at RT and then placing on ice. Use a vortex and/or thermomixer set at 37 °C and 350 rpm to ensure all amino acid stocks are fully dissolved.

NOTE: Cysteine may not fully dissolve; it can be added to the amino acid master mix as a suspension. Do not overheat or leave reagents on the thermomixer for an extended period of time.

3.3.2. In a 15 mL tube, add the appropriate volume amino acids to sterile DI water so that final concentration of each is 8 mM in the following order: ALA, ARG, ASN, ASP, GLN, GLU, GLY, HIS, ILE, LYS, MET, PHE, PRO, SER, THR, VAL, TRP, TYR, LEU, and CYS. After adding each amino acid, vortex the master mix solution. The volumes listed in **Table 2** will make up 2.4 mL of amino acid master mix.

3.3.3. Divide the 4x amino acid master mix into 200 µL aliquots in 2 mL tubes. Flash freeze each aliquot as performed in step 2.12. Immediately place into a refrigerator at -80°C until use.

### **3.4. Production of reaction-ready plasmid DNA template**

NOTE: Cell-free protein expression in this system has been optimized using the super folder green fluorescent protein (GFP) expression vector T7-pJL1-sfGFP (**Table of Materials**). It is recommended to use this plasmid as a control for cell-free reaction efficiency and the pJL1 backbone for the cloning and expression of other protein sequences. Other plasmid DNA templates can be used; however, it is important to note that transcription is controlled by a T7 promoter sequence and the presence of T7 RNA polymerase. A simple protocol for the large-scale production of any plasmid DNA template from transformed *E. coli* is described below.

3.4.1. Purify desired vector using a plasmid purification kit as per manufacturer's instruction (Table of Materials).

NOTE: Concentrating the plasmid DNA template as much as possible is recommended to meet the tight volume constraints of the cell-free reaction. In general, aim for a 750–1500 ng/μL working stock.

### 3.5. Production of reaction-ready mRNA template

NOTE: This section is optional. Protein expression has been tested using mRNA template generated from the in vitro transcription of the plasmid T7-pJL1-sfGFP by the listed T7 RNA polymerase (Table of Materials).

3.5.1. Prepare mRNA template from plasmid DNA encoding the protein of interest using the in vitro transcription reaction components in Table 3. Incubate reactions for 1 h at 37 °C in a thermocycler.

NOTE: It is recommended to perform 8–10x of these reactions in parallel to generate enough material.

3.5.2. Pool all transcription reactions. Purify using an mRNA purification and concentrator kit as per manufacturer's instruction (Table of Materials). Elute mRNA template into sterile DI water. Store mRNA template at -80 °C until use.

## 4. Performing cell-free protein expression reactions using *V. natriegens* crude extract

### 4.1. Cell-free protein expression using plasmid or linear DNA template

4.1.2. Remove 10x energy solution master mix and 4x amino acid master mix aliquots from the -80 °C refrigerator, thaw at RT, and place on ice. Remove the T7 RNA polymerase and RNase inhibitor stocks from the -20 °C refrigerator and place on ice. Thaw DNA template at RT and place on ice.

4.1.2. Prepare a cell-free reaction master mix as per Table 4 by adding each component in the following order to a 2 mL tube on ice: amino acid master mix, energy solution master mix, Mg-glutamate, K-glutamate, DNA template, PEG-8000, T7 RNA polymerase, and RNase inhibitor. Gently flick the tube after each addition to the master mix.

NOTE: If linear template is to be used for cell-free protein expression, add 5–10x more material as compared to plasmid template to obtain appreciable yields of protein.

4.1.3. Remove *V. natriegens* crude cell lysate prepared in step 2.12 from the -80 °C refrigerator and place on ice for 10–20 min until thawed. Add the appropriate volume crude cell extract to

the cell-free reaction master mix as per **Table 4** and gently mix by flicking or pipetting up and down.

#### **4.1.4. End-point cell-free protein expression using thermocycler**

4.1.4.1. Pipette 10  $\mu$ L of the cell-free reaction master mix to the bottom of a 96- or 384-well PCR plate. In between each transfer to the PCR plate, mix the master mix by flicking the tube gently.

NOTE: Cell-free reaction master mix should be well mixed at all times to maximize reaction reproducibility and cell-free protein expression in all samples.

4.1.5. Briefly centrifuge the plate at 1000  $\times g$  for 10 s to pool any master mix that may have become stuck on the sides of the wells. Seal the wells with a plate adhesive to prevent evaporation and then place the PCR plate into a thermocycler set at 26  $^{\circ}$ C with a heated lid set at 105  $^{\circ}$ C.

NOTE: The even heat distribution and heated lid of a thermocycler greatly improves protein expression yields.

4.1.6. Incubate the cell-free reactions for a minimum of 3 h. After incubation, expressed proteins can be purified, quantified, and used for downstream processes.

NOTE: Expressed proteins can be directly quantified in the cell-free reaction using a method of the user's choice. For example, fluorescent proteins can be quantified using an external standard curve or radioactivity can be measured if using a radiolabeled amino acid in the cell-free reaction. UV-visible spectroscopy or total protein assays are generally not recommended for directly measuring protein production in cell-free reactions without an initial purification.

4.1.7. Alternatively, monitor cell-free protein expression kinetics using a plate reader. Pipette 10  $\mu$ L of the cell-free reaction master mix to the bottom of a black 384-well assay plate with clear glass bottoms. Keep the assay plate on ice or work in a cold room while adding the master mix to ensure that the full kinetic profile is obtained. Seal the wells with a clear plate adhesive to prevent evaporation and then place the assay plate into a plate reader set at 26  $^{\circ}$ C.

4.1.8. Incubate the cell-free reactions for 3–6 h while monitoring the appropriate fluorescent excitation/emission wavelengths corresponding to the expressed protein. For example, monitor at Ex/Em = 485 nm/528 nm for sfGFP.

#### **4.2. Cell-free protein expression using mRNA template**

4.2.1. Thaw mRNA template prepared in step 3.5.2 at RT and place on ice.

4.2.2. Perform step 4.1.1 through step 4.1.6 as previously specified for linear or plasmid DNA template using **Table 4** to prepare an alternative cell-free reaction master mix for mRNA

template.

## 5. Calibration of *V. natriegens* cell-free reactions with sfGFP

NOTE: This section is optional. The optimal cell-free reaction ion concentration can vary slightly for each crude extract preparation based on the conditions used for cell lysis. Consider performing the optional cell-free reaction ion calibration protocol described below using sfGFP if reaction yields are significantly lower than expected (concentrations < 1.0 µg/mL).

5.1. Prepare the Mg<sup>2+</sup> and K<sup>+</sup> ion calibration solutions as specified in **Table 5** in sterile DI water from the 100 mM Mg-glutamate and 2000 mM K-glutamate stocks prepared in step 3.1.1. Place calibration solutions on ice until needed.

5.2. Following the calibration map in **Table 6**, pipette 1 µL of the Mg-glutamate and 2 µL of K-glutamate ion calibration solutions into the appropriate wells in a 384-well PCR plate.

5.2.1. The order of operations of this step is as follows: Pipette the Mg-glutamate ion calibration solution into the bottom of each well followed by the K-glutamate ion calibration solution onto the side of well without touching the liquid already present in the wells.

5.2.2. Seal the wells by placing an adhesive on top of the plate to prevent evaporation while preparing the calibration cell-free reaction master mix. Gently tap the 384-well plate to mix the Mg- and K-glutamate calibration solutions.

NOTE: A repeater pipette is highly recommended for completing this step reproducibly and quickly.

5.3. Prepare the calibration cell-free reaction master mix as specified in **Table 5** using T7-pJL1-sfGFP plasmid DNA template in a 2 mL tube. Add each component in the following order to the master mix: amino acid master mix, energy solution master mix, T7-pJL1-sfGFP DNA template, PEG-8000, T7 RNA polymerase, and RNase inhibitor. Gently flick the tube to mix after each component addition.

NOTE: Do not add Mg<sup>2+</sup> or K<sup>+</sup> to the calibration cell-free master mix.

5.4. Remove the adhesive from the plate. Carefully pipette 7 µL of the calibration cell-free reaction master mix on to the sides of the wells without touching the mixed ion calibration solution already present in the wells. Reseal the wells with the adhesive and gently tap the 384-well PCR plate to mix the cell-free master mix with the ion calibration solution.

NOTE: A repeater pipette is highly recommended for completing this step reproducibly and quickly.

5.5. Briefly centrifuge the plate 1000 x *g* for 10 s to pool any unmixed liquid that may have

become stuck on the sides of the wells. Place the 384-well plate into a thermocycler set at 26 °C with a heated lid set at 105 °C.

5.6. Incubate the cell-free reactions for 3 h. After incubation, transfer the contents of each well to a black 384-well assay plate with glass bottoms with a multi-channel pipette and read the fluorescence of sfGFP at Ex/Em = 485 nm/528 nm using a plate reader to determine the ion concentration combination that yields the highest amount of protein.

#### REPRESENTATIVE RESULTS:

The described protocol for protein production using *V. natriegens* cell-free expression system can be executed in 1–2 days by a single user, starting from inoculation of culture to protein available for downstream applications. Preparation of crude cell extracts and master mix stocks comprise a significant portion of this time; however, once prepared, most bulk reagents can be stored long term (**Table 7**) and used as needed, shortening the time needed to complete the protocol.

The expression system described is best used with plasmid DNA template or mRNA generated by in vitro transcription reactions. While linear DNA can also be used as template for protein production, it yields significantly lower amount of protein. For example, at optimal reactions conditions at 26 °C, a single 10 µL cell-free reaction can produce > 260 µg/mL of sfGFP in 3 hours using 0.3 pmol of plasmid DNA template or a comparable > 125 µg/mL of sfGFP using 14 pmol of mRNA transcript (**Figure 5A,B**). However, 0.3 pmol of linear DNA will produce significantly less protein (< 20 µg/mL). For each template type, the majority of the protein will be produced within 1–1.5 hours; however, it is recommended that reaction is run for a minimum of 3 hours. Cell-free reaction concentrations of sfGFP were determined via linear regression using a purified sfGFP standard curve measuring fluorescence at Ex/Em = 485 nm/528 nm.

The yield of protein production is significantly affected by the concentration of potassium and magnesium ions (K<sup>+</sup> and Mg<sup>2+</sup>, respectively). Under optimized conditions, it was found that the optimal Mg<sup>2+</sup> and K<sup>+</sup> ion concentrations will be 3.5 mM and 80 mM, respectively (**Figure 6A,B**). Deviations from the optimal ion concentrations may result in a decreased capacity for the cell-free expression system to produce protein with appreciable yields. Additional calibration may be necessary if reaction yields are significantly lower than expected. An optional protocol for ion calibration is described in section 5. This allows for some flexibility in compensating for crude cell extract variability incurred from individual cell lysis equipment and conditions.

#### FIGURE AND TABLE LEGENDS:

**Figure 1: A close-up view of the beaker and tube holder on the sonication platform.**

**Figure 2: Sonication equipment setup for the preparation of crude cell extract.**

**Figure 3: A view of the pellet after sonication and centrifugation.**

**Figure 4: Flash freezing dip for extract storage.**

**Figure 5: Representative results for *V. natriegens* cell-free protein synthesis using different template types.** (A) endpoint assay of sfGFP production using equimolar concentrations of plasmid and linear DNA template (0.3 pmol) as well as increasing concentrations of mRNA template. Cell-free sfGFP concentration was determined using a standard curve of purified sfGFP measured at Ex/Em = 485 nm/528 nm after 180 minutes of incubation at 26 °C at optimal reaction conditions in 10 µL volumes. (B) Kinetic assay of sfGFP production using equimolar concentrations of plasmid and linear DNA template as well as increasing concentrations of mRNA template. sfGFP measurements were taken every 3 minutes at Ex/Em = 485 nm/528 nm over 180 minutes of total incubation time at optimal reaction conditions in 10 µL volumes. For both endpoint and kinetic assays, samples were blank corrected using cell-free reactions supplemented with all components except template. The mean and standard deviations are shown (n = 3).

**Figure 6: Representative results for ion concentration calibration.** (A) *V. natriegens* cell-free reactions were supplemented with increasing concentrations of Mg<sup>2+</sup> and incubated at 26 °C for 180 minutes in 10 µL reactions. The total concentration of K<sup>+</sup> was 160 mM for all Mg<sup>2+</sup> concentrations. Cell-free sfGFP concentration was determined using a standard curve of purified sfGFP measured at Ex/Em = 485 nm/528 nm. (B) *V. natriegens* cell-free reactions were supplemented with increasing concentrations of K<sup>+</sup> and incubated at 26 °C for 180 minutes in 10 µL reactions. The total concentration of Mg<sup>2+</sup> was 3.5 mM for all K<sup>+</sup> concentrations. For both calibrations, samples were blank corrected using cell-free reactions supplemented with all components except template. The mean and standard deviations are shown (n = 3). This figure has been modified from Wiegand et al.<sup>9</sup>. Reprinted with permission from Wiegand, D.J., Lee, H.H., Ostrov, N., Church, G.M. Establishing a Cell-Free *Vibrio natriegens* Expression System. *ACS Synthetic Biology*. 7 (10), 2475–2479 (2018). Copyright 2018 American Chemical Society.

**Table 1: Reagents for the preparation of 1 L of LB-V2 bacterial growth media and 0.5 L of S30A cell lysis buffer.**

**Table 2: Reagents for the preparation of 5 mL of 10x energy solution master mix and 2.4 mL of 4x amino acid master mix.**

**Table 3: In vitro transcription components for mRNA generation.**

**Table 4: Components of optimized *V. natriegens* cell-free reaction master mix for DNA template and mRNA template.**

**Table 5: Ion concentration calibration master mixes.**

**Table 6: Ion calibration map.**

**Table 7: Cell-free storage conditions and shelf lives.**

**DISCUSSION:**



This protocol has been optimized for wild-type *V. natriegens* and bacterial growth media comprised of LB supplemented with V2 salts (**Table of Materials**). Other strains of *V. natriegens* can be similarly cultured to generate crude cell extracts for cell-free reactions; however, their use requires additional optimization of this protocol. Additionally, this cell-free protein expression system has been optimized using 3-phosphoglyceric acid (3-PGA) as the primary energy regeneration source. Other energy regeneration sources may be used; however, optimization of reagents and calibration will likely be required to obtain high yielding protein expression<sup>10, 11</sup>.

Specific attention to several critical steps in this protocol will ensure maximal extract productivity for high-yielding cell-free protein production. First, crude cell extract must be prepared from *V. natriegens* cell cultures harvested in a mid-exponential phase of growth; protein yield is maximal when cultures reach an  $OD_{600} = 1.0 \pm 0.2$ . While cell-free protein production is possible from cells harvested at a range of optical densities, we have previously found that cells harvested in an exponential state of growth yield significantly more protein<sup>9</sup>. The observed effects of optical density on crude cell extract performance are consistent with those reported for other cell-free expression systems derived from cells grown in batch culture conditions<sup>1</sup>. Because *V. natriegens* grows at a rapid rate, it is critical to closely monitor cultures' optical densities. In general, it is expected that *V. natriegens* cultures should reproducibly reach an  $OD_{600}$  of 1.0 within 1–1.5 hours using this protocol; however, individual growth conditions such as the use of baffled versus non-baffled flasks, which affects aeration, or air versus water incubation, which affects the rate and stability of incubation temperature, may alter growth time. Furthermore, it is generally recommended to culture at least 250 mL of *V. natriegens* in a 1 L baffled flask to ensure a large cell pellet at harvest for easy manipulation and transfer. This greatly improves the success of crude cell extract preparation as well as increases the total volume of extract produced from a pellet. When using smaller scale preparation, culture conditions and reagents can be adjusted appropriately. For large-scale fermentation, further optimization of culture conditions may be required. Finally, to ensure high protein yield, it is critical that cell pellets are processed immediately after harvesting, or within 1–2 days of storing at -80 °C.

The proper lysis of the cell pellet by pulse sonication is critical to the success of cell-free protein expression and is often the most difficult aspect of this protocol for new users. Typically, a well lysed pellet will yield a significant volume of liquid extract that is free of debris. The extract should be slightly viscous but can be easily pipetted when aliquoting into storage tubes before flash freezing in liquid nitrogen. **Figure 3** depicts a representation of a well lysed pellet (**Figure 3A**) in comparison to a poorly lysed pellet (**Figure 3B**) after the post lysis centrifugation step. A major indication of complete cell lysis is a crude cell extract total protein concentration > 20 mg/mL as determined by a total protein assay (step 2.13). Over-sonication or excessive heating of the crude cell extract will damage the cellular machinery, which cannot be determined without performing a cell-free reaction. Thus, it is highly beneficial to test extract efficiency with a control reaction before dedicating significant time and effort to downstream protein expression applications. While additional optimization may be necessary for different sonication equipment, the pulse sonication steps described have been highly reproducible in our hands.

The use of linear DNA template derived from PCR amplification, restriction enzyme digest, or

commercial gene synthesis can significantly increase the capacity for high-throughput and rapid protein production in cell-free expression systems<sup>24</sup>. While protein production from PCR amplified linear template has been demonstrated, the yield of these reactions are approximately 13.5-fold lower compared to reactions using plasmid DNA template at equimolar ratios<sup>9</sup>. This is primarily due to the instability of the linear DNA template which is likely degraded by endogenous nucleases present in *V. natriegens* crude cell extract. While lambda phage protein GamS has been previously used to protect Linear DNA template<sup>24,25</sup>, it was found to be incompatible with *V. natriegens* extracts<sup>9</sup>. Additionally, while increasing the concentration of linear DNA template may allow for a higher protein yield, its fast degradation in crude cell extract will still be a major problem.

A solution to overcoming linear DNA template degradation may be to supplement cell-free reactions with mRNA template generated from in vitro transcription of linear DNA. On the other hand, the use of an RNase inhibitor offers significant protection against mRNA transcript degradation and appreciable protein yields can be obtained in the 10  $\mu$ L cell-free reaction format (**Figure 5A,B**). Cloning of linear DNA into a circular template through TA ligation, TOPO cloning, Golden Gate assembly, or other recombination methods may be used to circumvent template degradation. Nevertheless, further approaches for inhibition of nuclease activity will be necessary for efficient protein expression using linear DNA template.

To date, several different approaches have been proposed for preparation of crude extract for cell-free protein expression<sup>9–11,26</sup>. In developing this protocol, we sought to maximize user accessibility, reduce overall cost, and minimize time-consuming steps. For example, a high protein yield is achieved using a simple two-step sonication-centrifugation process, and does not require cell homogenizers, lengthy dialysis steps or run-off reaction. It is simple to execute in a short period of time and does not require high level of laboratory expertise. Thus, it can help facilitate cell-free expression as a standard for translational academic research and industrial process design.

This protocol expands the toolkit available for investigation and utility of *V. natriegens*, a non-model organism with unique biological properties. Higher protein yield can be achieved by employing semi- or fully-continuous cell-free reactions, to allow for energy regeneration, resupplying of amino acids, and the removal of waste products<sup>3,5,27</sup>. Furthermore, the engineering of wild-type *V. natriegens* to produce DNase- or RNase-deficient strains, removal of deleterious and competing metabolic pathways, and expression of additional tRNAs could greatly enhance the production of proteins in this system<sup>28,29</sup>. As we unravel the biology underlying its rapid growth, further development of *V. natriegens* cell-free systems may accelerate bioproduction capabilities and enable robust expression of therapeutic peptides, small molecules, and synthetic materials.

#### **ACKNOWLEDGMENTS:**

This work was funded by the National Institute of General Medical Sciences 1U01GM110714-01 and Department of Energy DE-FG02-02ER63445. The authors would like to thank Dr. Richard Kohman, Dr. Jenny Tam, and Dr. Edgar Goluch for helpful advice on constructing the protocol

section of this manuscript.

#### DISCLOSURES:


DJW, NO, and GMC have filed a patent related to this work.

#### REFERENCES:

1. Kwon, Y.-C., Jewett, M.C. High-throughput preparation methods of crude extract for robust cell-free protein synthesis. *Scientific Reports*. **5**, 8663 (2015).
2. Schoborg, J.A. et al. A cell-free platform for rapid synthesis and testing of active oligosaccharyltransferases. *Biotechnology and Bioengineering*. **115** (3), 739–750 (2018).
3. Caschera, F., Noireaux, V. Synthesis of 2.3 mg/ml of protein with an all Escherichia coli cell-free transcription–translation system. *Biochimie*. **99**, 162–168 (2014).
4. Henrich, E., Hein, C., Dötsch, V., Bernhard, F. Membrane protein production in Escherichia coli cell-free lysates. *FEBS Letters*. **589** (15), 1713–1722 (2015).
5. Li, J., Wang, H., Kwon, Y.C. Establishing a high yielding streptomyces-based cell-free protein synthesis system. *Biotechnology and Bioengineering*. **114** (6), 1343–1353 (2017)
6. Moore, S.J., Lai, H.-E., Needham, H., Polizzi, K.M., Freemont, P.S. Streptomyces venezuelae TX-TL—a next generation cell-free synthetic biology tool. *Biotechnology Journal*. **12** (4), 1600678 (2017).
7. Wang, H., Li, J., Jewett, M.C. Development of a Pseudomonas putida cell-free protein synthesis platform for rapid screening of gene regulatory elements. *Synthetic Biology*. **3** (1), ysy003 (2018).
8. Kelwick, R., Webb, A.J., MacDonald, J.T., Freemont, P.S. Development of a Bacillus subtilis cell-free transcription-translation system for prototyping regulatory elements. *Metabolic Engineering*. **38**, 370–381 (2016).
9. Wiegand, D.J., Lee, H.H., Ostrov, N., Church, G.M. Establishing a Cell-Free Vibrio natriegens Expression System. *ACS Synthetic Biology*. **7** (10), 2475–2479 (2018).
10. Des Soye, B.J., Davidson, S.R., Weinstock, M.T., Gibson, D.G., Jewett, M.C. Establishing a High-Yielding Cell-Free Protein Synthesis Platform Derived from Vibrio natriegens. *ACS Synthetic Biology*. **7** (9), 2245–2255 (2018).
11. Failmezger, J., Scholz, S., Blombach, B., Siemann-Herzberg, M. Cell-Free Protein Synthesis From Fast-Growing Vibrio natriegens. *Frontiers in Microbiology*. **9**, 1146 (2018).
12. Moore, S.J., MacDonald, J.T., Wienecke, S. Rapid acquisition and model-based analysis of cell-free transcription–translation reactions from nonmodel bacteria. *Proceedings of the National Academy of Sciences of the United States of America*. **115** (19), E4340–E4349 (2018).
13. Eagon, R.G. Pseudomonas natriegens, a marine bacterium with a generation time of less than 10 minutes. *Journal of Bacteriology*. **83**, 736–737 (1962).
14. Weinstock, M.T., Hesek, E.D., Wilson, C.M., Gibson, D.G. Vibrio natriegens as a fast-growing host for molecular biology. *Nature Methods*. **13** (10), 849–851 (2016).
15. Lee, H.H. et al. Vibrio natriegens, a new genomic powerhouse. *bioRxiv*. 058487, doi: 10.1101/058487 (2016).
16. Lee, H.H., Ostrov, N., Gold, M.A., Church, G.M. Recombineering in Vibrio natriegens. *bioRxiv*. 130088, doi: 10.1101/130088 (2017).
17. Schleicher, L. et al. Vibrio natriegens as Host for Expression of Multisubunit Membrane Protein Complexes. *Frontiers in Microbiology*. **9**, 2537 (2018).

18. Fernández-Llamas, H., Castro, L., Blázquez, M.L., Díaz, E., Carmona, M. Speeding up bioproduction of selenium nanoparticles by using *Vibrio natriegens* as microbial factory. *Scientific Reports*. **7** (1), 16046 (2017).
19. Aiyar, S.E., Gaal, T., Gourse, R.L. rRNA promoter activity in the fast-growing bacterium *Vibrio natriegens*. *Journal of Bacteriology*. **184** (5), 1349–1358 (2002).
20. Hoffart, E. et al. High substrate uptake rates empower *Vibrio natriegens* as production host for industrial biotechnology. *Applied and Environmental Microbiology*. **83**, e01614-17 (2017).
21. Long, C.P., Gonzalez, J.E., Cipolla, R.M., Antoniewicz, M.R. Metabolism of the fast-growing bacterium *Vibrio natriegens* elucidated by  $^{13}\text{C}$  metabolic flux analysis. *Metabolic Engineering*. **44**, 191–197 (2017).
22. Shin, J., Noireaux, V. Efficient cell-free expression with the endogenous *E. coli* RNA polymerase and sigma factor 70. *Journal of Biological Engineering*. **4**, 8 (2010).
23. Sitaraman, K. et al. A novel cell-free protein synthesis system. *Journal of Biotechnology*. **110** (3), 257–263 (2004).
24. Sun, Z.Z., Yeung, E., Hayes, C.A., Noireaux, V., Murray, R.M. Linear DNA for rapid prototyping of synthetic biological circuits in an *Escherichia coli* based TX-TL cell-free system. *ACS Synthetic Biology*. **3** (6), 387–397 (2014).
25. Seki, E., Matsuda, N., Yokoyama, S., Kigawa, T. Cell-free protein synthesis system from *Escherichia coli* cells cultured at decreased temperatures improves productivity by decreasing DNA template degradation. *Analytical Biochemistry*. **377** (2), 156–161 (2008).
26. Failmezger, J., Rauter, M., Nitschel, R., Kraml, M., Siemann-Herzberg, M. Cell-free protein synthesis from non-growing, stressed *Escherichia coli*. *Scientific Reports*. **7** (1), 16524 (2017).
27. Shirokov, V.A., Simonenko, P.N., Biryukov, S.V., Spirin, A.S. Continuous-Flow and Continuous-Exchange Cell-Free Translation Systems and Reactors. *Cell-Free Translation Systems*. 91–107 (2002).
28. Michel-Reydellet, N., Woodrow, K., Swartz, J. Increasing PCR fragment stability and protein yields in a cell-free system with genetically modified *Escherichia coli* extracts. *Journal of Molecular Microbiology and Biotechnology*. **9** (1), 26–34 (2005).
29. Swartz, J.R. Expanding biological applications using cell-free metabolic engineering: An overview. *Metabolic Engineering*. **50**, 156–172 (2018).





## Sonication Equipment:

(1) Rod and Clamp

(2) Sonicator with Tip

(3) Tube Holder


(4) 600 mL Beaker with Ice

(5) Adjustable Stage

(6) Sonicator Control Box


Figure\_4

[Click here to access/download;Figure;Figure\\_4\\_Flash\\_Freeze\\_Close\\_Up.jpg](#) 








A.



B.







	Preparation of LB-V2 Bacterial Growth M	
Component	Quantity (g)	Final Concentration (mM)
LB Broth (Miller)	25	
NaCl	11.69	200
MgCl <sub>2</sub>	0.00	23.1
KCl	0.00	4.2

	Preparation of S30A Lysis Buffer	
Component	Quantity (g)	Final Concentration (mM)
Tris Solution (pH 8.0) - 1 M (mL)*	25	50
Mg-glutamate	0.00	14
K-glutamate	0.00	60
Dithiothreitol (DTT) - 1 M (mL)*	1	2

Media
Final Volume (L)
1

Final Volume (L)
0.5

	Pre
Component	Stock Concentration (mM)
HEPES-KOH pH 8	1750
ATP	100
GTP	100
CTP	100
UTP	100
tRNA from E. coli MRE 600 (mg/mL)*	100
Coenzyme A Hydrate	200
NAD	200
cAMP	650
Folinic Acid	100
Spermidine	1600
3-PGA	2000
Sterile Deionized Water	

	P
Component	Stock Concentration (mM)
ALA	168
ARG	168
ASN	168
ASP	168
GLN	168
GLU	168
GLY	168
HIS	168
IIE	168
LYS	168
MET	168
PHE	168
PRO	168
SER	168
THR	168
VAL	168
TRP	168
TYR	168
LEU	140
CYS	168
Sterile Deionized Water	

Preparation of 10x Energy Solution Master Mix		
Final Concentration (mM)	Quantity (μL)	Final Volume (μL)
500	1428.57	5000
15	750.00	
15	750.00	
9	450.00	
9	450.00	
2	100.00	
2.6	65.00	
3.3	82.50	
7.5	57.69	
0.7	35.00	
10	31.25	
300	750.00	
	49.99	

Preparation of 4x Amino Acid Master Mix		
Final Concentration (mM)	Quantity (μL)	Final Volume (μL)
8	114.3	2400
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	137.1	
8	114.3	
	91.4	

	T7 RNA Polymerase	
Component	Stock (mM)	Final Concentration (mM)
10x RNAPol Reaction Buffer		
ATP	100	0.5
GTP	100	0.5
CTP	100	0.5
UTP	100	0.5
DNA Template (ng/μL)*	1000	500
T7 RNA Polymerase	200	2.6
Rnase Inhibitor, Murine	200	3.3
Sterile Deionized Water		
Reaction Volume (μL):	20	

ase In Vitro Transcription Reactions	
Quantity (μL) 1x Reaction	Quantity (μL) 50x Reactions
1.00	50
0.10	5
0.10	5
0.10	5
0.10	5
0.10	5
0.50	25
2.00	100
0.50	25
15.60	780

	Cell-free Re	
Component	Stock Concentration (mM)	Final Concentration (mM)
Extract (%)*		25
Mg-glutamate	100	3.5
K-glutamate	2000	80
4x Amino Acid Master Mix	8.0	2
10x Energy Solution Master Mix		
Plasmid DNA (ng/ $\mu$ L)*	1000	500
50% PEG-8000 (%)*	50	2
T7 RNA Polymerase		
RNase Inhibitor, Murine		
Sterile Deionized Water		
Reaction Volume ( $\mu$ L):	10	

	Alternative Cell-free Reacti	
Component	Stock Concentration (mM)	Final Concentration (mM)
Extract (%) *		25
Mg-glutamate	100	3.5
K-glutamate	2000	80
4x Amino Acid Master Mix	8.0	2
10x Energy Solution Master Mix		
mRNA Template (ng/ $\mu$ L)*	2000	4000
50% PEG-8000 (%)*	50	2
RNase Inhibitor, Murine		
Sterile Deionized Water		
Reaction Volume ( $\mu$ L):	10	



Reaction Master Mix	
Quantity (μL) 1x Reaction	Quantity (μL) 50x Reactions
2.50	125.00
0.35	17.50
0.40	20.00
2.50	125.00
1.00	50.00
0.50	25.00
0.40	20.00
1.00	50.00
0.10	5.00
1.25	62.50

Reaction Master Mix for mRNA Template	
Quantity (μL) 1x Reaction	Quantity (μL) 50x Reactions
2.50	125.00
0.35	17.50
0.40	20.00
2.50	125.00
1.00	50.00
2.00	100.00
0.40	20.00
0.10	5.00
0.75	37.50

Mg <sup>2+</sup> Calibration		Quantity (μL) 1x Reaction
Final (mM)	Stock	100 mM Mg-Glu
2.5	0	0.00
3.5	1	0.10
4.5	2	0.20
5.5	3	0.30
Reaction Volume (μL):	10	

K <sup>+</sup> Calibration		Quantity (μL) 1x Reaction
Final (mM)	Stock	2000 mM K-Glu
40	30	0.15
80	70	0.35
160	150	0.75
320	310	1.55
Reaction Volume (μL):	10	

	Ion Calibration Cell	
Component	Stock Concentration (mM)	Final Concentration (mM)
Extract (%)*		25
Mg-glutamate	Variable	Variable
K-glutamate	Variable	Variable
4x Amino Acid Master Mix	8.0	2
10x Energy Solution Master Mix		
Plasmid DNA (ng/μL)*	1000	250
50% PEG-8000 (%)*	50	2
T7 RNA Polymerase		
RNase Inhibitor, Murine		
Sterile Deionized Water		
Reaction Volume (μL):	10	

Quantity (μL) 1x Reaction	Quantity (μL) 100x Reactions
diH <sub>2</sub> O	100 mM Mg-Glu
1.00	0
0.90	10
0.80	20
0.70	30

Quantity (μL) 1x Reaction	Quantity (μL) 100x Reactions
diH <sub>2</sub> O	2000 mM K-Glu
1.85	12
1.65	28
1.25	60
0.45	124

I-free Reaction Master Mix	
Quantity (μL) 1x Reaction	Quantity (μL) 50x Reactions
2.50	125.00
1.00	50.00
2.00	100.00
2.50	125.00
1.00	50.00
0.25	12.50
0.40	20.00
1.00	50.00
0.10	5.00
0.00	0.00

Quantity (μL) 100x Reactions
Deionized H <sub>2</sub> O
100
90
80
70

Quantity (μL) 100x Reactions
Deionized H <sub>2</sub> O
148
132
100
36

CF Ion Calibration Map		40 mM K <sup>+</sup>			80 mM K <sup>+</sup>	
		1	2	3	4	5
2.5 mM Mg <sup>2+</sup>	A					
3.5 mM Mg <sup>2+</sup>	B					
4.5 mM Mg <sup>2+</sup>	C					
5.5 mM Mg <sup>2+</sup>	D					

	160 mM K <sup>+</sup>			320 mM K <sup>+</sup>		
6	7	8	9	10	11	12

	Storage Conditions and Shelf Lives of CF Components	
Component	Storage Location	Shelf Life
Sterile LB-V2 Growth Media	4 °C	3-6 months
<i>V. natriegens</i> Crude Cell Extract	-80 °C	1-3 weeks
100 mM Mg-Glutamate	Room Temp	6 months
2000 mM K-Glutamate	Room Temp	6 months
50% PEG-8000	Room Temp	6 months
10x Energy Solution Master Mix	-80 °C	3-6 months
4x Amino Acid Master Mix	-80 °C	3-6 months
Plasmid/Linear DNA Template	-20 °C	6-12 months
mRNA Template	-80 °C	3-4 weeks

Name of Material/Equipment	Company	Catalog Number	Comments/Description
15 mL Tubes	Corning	352196	
2 mL Tubes	Eppendorf	22363352	
384-well Black Assay Plates	Corning	3544	
384-well PCR Plates	Eppendorf	951020702	
50 mL Tubes	Corning	352070	
96-well PCR Plates	Eppendorf	30129300	
Adenosine 3',5'-cyclic monophosphate sodium salt monohydrate	Sigma	A6885	
Adenosine 5'-triphosphate - 100 mM	NEB	N0450L	
Applied Biosystems Veriti 384-well Thermocycler	ThermoFisher	4388444	
Assay Plate Adhesives	BioRad	MSB1001	
$\beta$ -Nicotinamide adenine dinucleotide hydrate (NAD)	Sigma/Roche	10127965001	
Coenzyme A hydrate	Sigma	C4283	
Cytidine 5'-triphosphate - 100 mM	NEB	N0450L	
D-(-)-3-Phosphoglyceric acid disodium salt (3-PGA)	Sigma	P8877	
Dewar Flask - 4L	ThermoScientific	10-194-100C	
DL-Dithiothreitol solution - 1 M	Sigma	42816	
Folinic acid calcium salt hydrate	Sigma	47612	
Glacial Acetic Acid	Sigma	A6283	
Guanosine 5'-triphosphate - 100 mM	NEB	N0450L	
HEPES	Sigma	H3375	
L-Glutamic acid hemimagnesium salt tetrahydrate	Sigma	49605	
L-Glutamic acid potassium salt monohydrate	Sigma	G1149	
LB Broth (Miller)	Sigma	L3522	
Magnesium chloride ( $\text{MgCl}_2$ )	Sigma	M8266	
Plasmid pJL1-sfGFP	Addgene	69496	
Plasmid Plus <i>Maxi</i> kit	Qiagen	12963	
Poly(ethylene glycol) (PEG)-8000	Sigma	89510	
Potassium chloride (KCl)	Sigma	P9333	
Potassium hydroxide Pellets	Sigma/Roche	1050121000	
Q125 Sonicator and CL-18 probe with a 1/8-inch tip	Qsonica	4422	
RNA Clean and Concentrator Kit	Zymo	R1013	



RNase Inhibitor, Murine	NEB	M0314	
RTS Amino Acid Sampler	Biotechrabbit	BR1401801	
Sodium chloride (NaCl)	Sigma	S7653	
Spermidine	Sigma	S0266	
T7 RNA Polymerase	NEB	M0251	
Tris Solution (pH 8.0) - 1 M	Invitrogen	AM9856	
tRNA from E. coli MRE 600	Sigma/Roche	10109541001	
Uridine 5'-triphosphate - 100 mM	NEB	N0450L	
<i>Vibrio natriegens</i> (Wild-type) Lyophilized Stock	ATCC	14048	



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

A Protocol for Cell-free Protein Expression Using the Rapidly Growing Bacterium *Vibrio Natriegens*

Author(s):

Daniel J. Wiegand, Henry H. Lee, Nili Ostrov, George M. Church

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐

Standard Access

☒

Open Access

Item 2: Please select one of the following items:

☒

The Author is **NOT** a United States government employee.

☐

The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐

The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

## ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole



## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:

George M. Church

Department:

Dept. of Genetics

Institution:

Harvard Medical School

Title:

Professor of Genetics

Signature:



Date:

12/31/2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

**Response to Reviewers for Manuscript:****A Protocol for Cell-Free Protein Expression Using the Rapidly Growing Bacterium *Vibrio natriegens***

Daniel J. Wiegand, Henry H. Lee, Nili Ostrov, & George M. Church

**Editorial comments:**

Changes to be made by the author(s):

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.
2. Please revise lines 594-597 to avoid previously published text.

The previously published text has been revised to the following:

*"To date, several different approaches have been proposed for preparation of crude extract for cell-free protein expression. In developing this protocol, we sought to maximize user accessibility, reduce overall cost and minimizing time consuming steps. "*

3. Please obtain explicit copyright permission to reuse any figures from a previous publication. Explicit permission can be expressed in the form of a letter from the editor or a link to the editorial policy that allows re-prints. Please upload this information as a .doc or .docx file to your Editorial Manager account. The Figure must be cited appropriately in the Figure Legend, i.e. "This figure has been modified from [citation]."

A document indicating the copyright permission for Figure 6 has been obtained from ACS Synthetic Biology and has been uploaded to Editorial Manager. The following has been added to the legend of Figure 6:

*"This figure has been modified from Wiegand, D.J., Lee, H.H., Ostrov, N., Church, G.M. Establishing a Cell-Free Vibrio natriegens Expression System. ACS Synthetic Biology. 7 (10), 2475-2479 (2018)." Reprinted with permission. Copyright 2018 American Chemical Society."*

4. Please upload each Figure individually to your Editorial Manager account as a .png, .tiff, .pdf, .svg, .eps, .psd, or .ai file.

Figures 1,2, 4-6 have been re-uploaded as high resolution .png.

5. Figure 3 is missing from the submission. Please upload it to your Editorial Manager account as a .png, .tiff, .pdf, .svg, .eps, .psd, or .ai file.

Figure 3 will be obtained during filming process.

6. Figures 5 and 6: Please define error bars in the figure legend.

Both Figure 5 and 6 have been updated with an additional sentence to define the error bars. In both Figures, the following sentence has been added:

*“The mean and standard deviations are shown (N=3).”*

7. Table 1.1-Table 5.2: Please remove the manufacturer information from all tables. In these tables, please indicate the volume/mass of each component if relevant. Please renumber the tables as Table 1, Table 2, Table 3, Table 4, Table 5,... Table 9, and upload each Table individually to your Editorial Manager account as an .xls or .xlsx file. Please also consider merging some of the tables to reduce the total number of figures.

Manufacturer information has been removed from all tables. Tables have been renumbered as requested and uploaded individually. The text has been appropriately updated to reflect this.

8. Table 1.1: Please use subscripts in chemical formulae to indicate the number of atoms (MgCl<sub>2</sub>).

The component MgCl<sub>2</sub> has been updated to MgCl<sub>2</sub> in Table 1.1.

9. Table 4.1, 4.2, 5.1, etc.: Please use the micro symbol  $\mu$  instead of u. Please abbreviate liters to L to avoid confusion.

All instances of u have been updated to the micro symbol  $\mu$  for all Tables.

10. Table 5.2: Please use superscripts to indicate ion charge (Mg<sup>2+</sup>, K<sup>+</sup>).

Ion charges in Tables 5.2A & 5.2B have been updated with superscripts.

11. Table of Equipment and Materials: Please sort the items in alphabetical order according to the name of material/equipment.

Table of Equipment and Materials has been updated with full chemical names and sorted alphabetically.

12. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents. You may use the generic term followed by “(see Table of Materials)” to draw the readers’ attention to specific commercial names. Examples of commercial sounding language in your manuscript are: Falcon, Eppendorf, Qsonica Q125, Biotechrabbit, etc.

All instances of commercial language (Eppendorf, Falcon, Qsonica, Biotechrabbit, ATCC, NEB) have been removed from the manuscript and are listed in the Table of Materials.

13. Please revise the protocol text to avoid the use of any personal pronouns (e.g., “we”, “you”, “our” etc.).

All instances of personal pronouns have been removed from the protocol text.

14. Lines 93-96, 132-136, 229-237, 265-269, 289-297, etc.: The Protocol should contain only action items that direct the reader to do something. Please write the text in the imperative tense. Any text that cannot

be written in the imperative tense may be added as a “NOTE”. Please move the discussion about the protocol to the Discussion.

These text sections have been modified appropriately without removing critical information for protocol users.

15. In the JoVE Protocol format, “Notes” should be concise and used sparingly. They should only be used to provide extraneous details, optional steps, or recommendations that are not critical to a step. Any text that provides details about how to perform a particular step should either be included in the step itself or added as a sub-step. Please consider moving some of the notes about the protocol to the discussion section.

General notes have been moved to the discussion section.

16. Please revise the Protocol steps so that individual steps contain only 2-3 actions per step and a maximum of 4 sentences per step. Use sub-steps as necessary.

Protocol steps have been updated accordingly.

17. After you have made all the recommended changes to your protocol (listed above), please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol.

18. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense. Notes cannot usually be filmed and should be excluded from the highlighting.

19. Please include all relevant details that are required to perform the step in the highlighting. For example: If step 2.5 is highlighted for filming and the details of how to perform the step are given in steps 2.5.1 and 2.5.2, then the sub-steps where the details are provided must be highlighted.

Protocol steps have been highlighted accordingly.

## Reviewers' comments:

### Reviewer #1:

#### Manuscript Summary:

The authors describe a protocol for generation cell-free extracts derived from *Vibrio natriegens* for subsequent use in (standard) coupled in vitro transcription/translation routines. This manuscript is based on a previous contribution by the same authors, published recently in *ASC Synthetic Biology*, 7 (10), 2475-2479, 2018.

#### Major Concerns:

This protocol might be a useful addition for the audience, motivated to step into the large and (ever since) ambitious field of cell free protein synthesis and therefore might be valid for distribution among the already exciting (numerous) protocols. However, I am sorry to state that for common cell-free ps 'experts'



this protocol is missing certain 'Vibrio-specific' topics, convincing this audience that this (novel) host is more attractive as namely systems from *E. coli*, yeasts, or wheat germ, just to name a few of these standard systems. As major topic the authors claimed that the protocol as 'rapid' (presumably to other) comparable protocols. I am surprised to notice, that the entire manuscript is more or less based on standard S30 extract formation routines, being well known from Zubay, Pratt, Swartz, Spirin, just name a few. In this respect it is a well-established standard to use (ultra) sonification, or high-pressure homogenization routines to gain cell-free extracts. As well it is a standard (optimization) routine to testify the K/Mg optimum beside providing other mixture of energy, or amino acids as such. Besides that, the authors are using the even well-established T7 Promotor to provide T7 polymerase for coupled TR/TL. Besides the use of linear DNA templates or 'Reaction ready mRNA Templates' which is the basis of cell free PS ever since. I can't see methods beyond the ever since applied routines from *E. coli*, that have been specifically (and exclusively) developed for *Vibrio* to justify this statement of having a novel and even more 'rapid' protocol at hand. That's why I think that the chosen title is most misleading and should be simplified to the state of the manuscript: (An S30-based) Protocol for Protein Production using *V. nat.* for cfps.

We appreciate the reviewer's comments and suggestion. We will alter the title of the manuscript to be: *"A Protocol for Cell-Free Protein Expression Using the Rapidly Growing Bacterium V. natriegens"*.

#### Minor Concerns:

Sorry, but I don't like the term 'Yield' (g/g; mol/mol) in this respect, since the authors exclusively are arguing in 'concentration or titer' (g/L, M) units. However, the authors stated on the 'high yield' of their provided *Vibrio* system and claimed a 'titer' of >260g/mL. Nonetheless I can't find hints of their applied quantification method: As this manuscript has to be organized as a protocol type, the routines for plausible product quantification are to included. This e.g. covers the quantification of GFP from external quantified GFP standards, molecular extinction/fluoresc. coefficient, and/or radioactive labels and the avcording statements of the obtained rates (g/h), productivities (g/L/h), and final titers (g/L).

We thank the reviewer for this comment. We have changed 'GFP yield' to 'GFP concentration' where applicable to rectify this inconsistency. Our quantification method for determining sfGFP concentration in *V. natriegens* cell-free reactions were described in the legends of Figures 5 and 6. We have added additional text to make this clearer in the representative results section (Lines: 382-384). We have added note with suggestions and recommendations for performing protein quantification (Lines: 299-304).

#### Reviewer #2:

##### Manuscript Summary:

Wiegand et. al. describe a useful protocol for the preparation of a cell-free extract based on *vibrio natriegens*. Based on the growing interest in using cell-free expression systems and the need for reproducible and low-cost procedures to prepare the reactions, this protocol will be of interest to a wide community. The protocol follows a recently published manuscript in ACS Synthetic Biology, where it was used and optimized.

Major Concerns: None

Minor Concerns: None



ACS Reprint Permissions &amp; Policies:

[https://pubs.acs.org/page/copyright/permissions\\_otherpub.html](https://pubs.acs.org/page/copyright/permissions_otherpub.html)


RightsLink®

Home

Cr  
AccACS Publications  
Most Trusted. Most Cited. Most Read.

**Title:** Establishing a Cell-Free *Vibrio natriegens* Expression System

**Author:** Daniel J. Wiegand, Henry H. Lee, Nili Ostrov, et al

**Publication:** ACS Synthetic Biology

**Publisher:** American Chemical Society

**Date:** Oct 1, 2018

Copyright © 2018, American Chemical Society

[LOGIN](#)

If you're a [copyright.com](#) user, you can login to RightsLink using your [copyright.com](#) credentials.

Already a [RightsLink](#) user or want to [learn more?](#)

## Quick Price Estimate

Permission for this particular request is granted for print and electronic formats, and translations, at no charge. Figures and tables may be modified. Appropriate credit should be given. Please print this page for your records and provide a copy to your publisher. Requests for up to 4 figures require only this record. Five or more figures will generate a printout of additional terms and conditions. Appropriate credit should read: "Reprinted with permission from {COMPLETE REFERENCE CITATION}. Copyright {YEAR} American Chemical Society." Insert appropriate information in place of the capitalized words.

If credit is given to another source for the material you requested, permission must be obtained from that source.

I would like to...



reuse in a Book/Encyclopedia/Monograph reuse in a Journal reuse in a Magazine reuse in a Newspaper/Newsletter reuse in an Application/Technical Report post on Internet/Website post on a Controlled Access Website/Intranet reuse in Conference Proceedings reuse in a Thesis/Dissertation reuse in Classroom reuse as an Image for a Cover reuse in an Annual Report make Multiple Photocopies make a Single Copy reuse in Training Materials

This service provides permission for reuse only. If you do not have a copy of the article you are using, you may copy and paste the content and reuse according to the terms of your agreement. Please be advised that obtaining the content you license is a separate transaction not involving Rightslink.

**Note: Individual Scheme and Structure reuse is free of charge and does not require a license. If the scheme or structure is identified as a Figure in the article, permission is required.**

Requestor Type



make a selection Author (original work) Author's Employer For Profit Non-profit

Portion



make a selection Table/Figure/Micrograph Full article 50% or more of original article Less than 50% of original article Excerpt (up to 400 words) Abstract

Number of  
Table/Figure/Micrographs



Format



make a selection Print Electronic Print and Electronic

Select your currency

USD - \$ EUR - € GBP - £ JPY - ¥ CHF - CHF CAD - \$ AUD -  
\$

Quick Price

Click Quick Price

QUICK PRICE

CONTINUE

To request permission for a type of use not listed, please contact [the publisher](#) directly.

Copyright © 2019 [Copyright Clearance Center, Inc.](#) All Rights Reserved. [Privacy statement.](#) [Terms and Conditions.](#)  
Comments? We would like to hear from you. E-mail us at [customercare@copyright.com](mailto:customercare@copyright.com)



Table 1 A	Preparation
Component	Quantity (g)
LB Broth (Miller)	25
NaCl	11.69
MgCl <sub>2</sub>	2.20
KCl	0.31

Table 1 B	Quantity (g)
Component	Quantity (g)
Tris Solution (pH 8.0) - 1 M (mL)*	25
Mg-glutamate	2.72
K-glutamate	6.10
DTT - 1 M (mL)*	1

Table 2 A	Stock Concentration (mM)
Component	Stock Concentration (mM)
HEPES-KOH pH 8	1750
ATP	100
GTP	100
CTP	100
UTP	100
tRNA from E. coli MRE 600 (mg/mL)*	100
Coenzyme A hydrate	200
NAD	200
cAMP	650
Folinic Acid	100
Spermidine	1600
3-PGA	2000
Sterile Deionized Water	

Table 2 B	Stock Concentration (mM)
Component	Stock Concentration (mM)
ALA	168
ARG	168
ASN	168
ASP	168
GLN	168
GLU	168
GLY	168
HIS	168
IIE	168
LYS	168

MET	168
PHE	168
PRO	168
SER	168
THR	168
VAL	168
TRP	168
TYR	168
LEU	140
CYS	168
Sterile Deionized Water	

Table 3	
Component	Stock (mM)
10X RNAPol Reaction Buffer	
ATP	100
GTP	100
CTP	100
UTP	100
DNA Template (ng/μL)*	1000
T7 RNA Polymerase	200
Rnase Inhibitor, Murine	200
Sterile Deionized Water	
Reaction Volume (μL):	20

Table 4 A	
Component	Stock Concentration (mM)
Extract (%) *	
Mg-glutamate	100
K-glutamate	2000
4X Amino Acid Master Mix	8.0
10X Energy Solution Master Mix	
Plasmid DNA (ng/μL) *	1000
50% PEG-8000 (%)*	50
T7 RNA Polymerase	
RNase Inhibitor, Murine	
Sterile Deionized Water	
Reaction Volume (μL):	10

Table 4 B	
Component	Stock Concentration (mM)

Extract (%) *	
Mg-glutamate	100
K-glutamate	2000
4X Amino Acid Master Mix	8.0
10X Energy Solution Master Mix	
mRNA Template (ng/ $\mu$ L)*	2000
50% PEG-8000 (%)*	50
RNase Inhibitor, Murine	
Sterile Deionized Water	
<b>Reaction Volume (<math>\mu</math>L):</b>	<b>10</b>

Table 5 A - Mg <sup>2+</sup> Calibration	
Final (mM)	Stock
2.5	0
3.5	1
4.5	2
5.5	3
<b>Reaction Volume (<math>\mu</math>L):</b>	<b>10</b>

Table 5 B - K <sup>+</sup> Calibration	
Final (mM)	Stock
40	30
80	70
160	150
320	310
<b>Reaction Volume (<math>\mu</math>L):</b>	<b>10</b>

Table 5 C	
Component	Stock Concentration (mM)
Extract (%) *	
Mg-glutamate	Variable
K-glutamate	Variable
4X Amino Acid Master Mix	8.0
10X Energy Solution Master Mix	
Plasmid DNA (ng/ $\mu$ L) *	1000
50% PEG-8000 (%) *	50
T7 RNA Polymerase	
RNase Inhibitor, Murine	
Sterile Deionized Water	
<b>Reaction Volume (<math>\mu</math>L):</b>	<b>10</b>

Table 7	Storage Conditions & Shelf Life
Component	Storage Location
Sterile LB-V2 Growth Media	4 °C
<i>V. natriegens</i> Crude Cell Extract	-80 °C
100 mM Mg-Glutamate	Room Temp
2000 mM K-Glutamate	Room Temp
50% PEG-8000	Room Temp
10X Energy Solution Master Mix	-80 °C
4X Amino Acid Master Mix	-80 °C
Plasmid/Linear DNA Template	-20 °C
mRNA Template	-80 °C

Preparation of LB-V2 Bacterial Growth Media	
Final Concentration (mM)	Final Volume (L)
	1
200	
23.1	
4.2	

Preparation of S30A Lysis Buffer	
Final Concentration (mM)	Final Volume (L)
50	0.5
14	
60	
2	

Preparation of 10X Energy Solution Master Mix		
Final Concentration (mM)	Quantity (µL)	Final Volume (µL)
500	1428.57	5000
15	750.00	
15	750.00	
9	450.00	
9	450.00	
2	100.00	
2.6	65.00	
3.3	82.50	
7.5	57.69	
0.7	35.00	
10	31.25	
300	750.00	
	49.99	

[illegible]

8	114.3	2400
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	114.3	
8	137.1	
8	114.3	
	91.4	

T7 RNA Polymerase <i>In vitro</i> Transcription Reactions		
Final Concentration (mM)	Quantity (μL) 1x Reaction	Quantity (μL) 50x Reaction
	1.00	50
0.5	0.10	5
0.5	0.10	5
0.5	0.10	5
0.5	0.10	5
500	0.50	25
2.6	2.00	100
3.3	0.50	25
	15.60	780

Cell-free Reaction Master Mix		
Final Concentration (mM)	Quantity (μL) 1x Reaction	Quantity (μL) 50x Reactions
25	2.50	125.00
3.5	0.35	17.50
80	0.40	20.00
2	2.50	125.00
	1.00	50.00
500	0.50	25.00
2	0.40	20.00
	1.00	50.00
	0.10	5.00
	1.25	62.50

Alternative Cell-free Reaction Master Mix for mRNA Template		
Final Concentration (mM)	Quantity (μL) 1x Reaction	Quantity (μL) 50x Reactions



25	2.50	125.00
3.5	0.35	17.50
80	0.40	20.00
2	2.50	125.00
	1.00	50.00
4000	2.00	100.00
2	0.40	20.00
	0.10	5.00
	0.75	37.50

Quantity (μL) 1x Reaction	Quantity (μL) 1x Reaction	Quantity (μL) 100x Reactions
100 mM Mg-Glu	diH <sub>2</sub> O	100 mM Mg-Glu
0.00	1.00	0
0.10	0.90	10
0.20	0.80	20
0.30	0.70	30

Quantity (μL) 1x Reaction	Quantity (μL) 1x Reaction	Quantity (μL) 100x Reactions
2000 mM K-Glu	diH <sub>2</sub> O	2000 mM K-Glu
0.15	1.85	12
0.35	1.65	28
0.75	1.25	60
1.55	0.45	124

Ion Calibration Cell-free Reaction Master Mix		
Final Concentration (mM)	Quantity (μL) 1x Reaction	Quantity (μL) 50x Reactions
25	2.50	125.00
Variable	1.00	50.00
Variable	2.00	100.00
2	2.50	125.00
	1.00	50.00
250	0.25	12.50
2	0.40	20.00
	1.00	50.00
	0.10	5.00
	0.00	0.00

If Lives of CF Components	
	<b>Shelf Life</b>
	3-6 months
	1-3 weeks
	6 months
	6 months
	6 months
	3-6 months
	3-6 months
	6-12 months
	3-4 weeks





Quantity (μL) 100x Reactions
diH <sub>2</sub> O
100
90
80
70

Quantity (μL) 100x Reactions
diH <sub>2</sub> O
148
132
100
36

Table 6: Ion Calibration Map		CF	40 mM K+			
		1	2	3	4	
2.5 mM Mg2+	A					
3.5 mM Mg2+	B					
4.5 mM Mg2+	C					
5.5 mM Mg2+	D					

80 mM K+		160 mM K+			320 mM K+	
5	6	7	8	9	10	11

12